|

Belantamab Mafodotin-Blmf Clinical Trials

1 actively recruiting trial

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Hellenic Society of Hematology1

Indications

  • Corneal Disease1
  • Haematologic Disease1
  • Gammopathy, Monoclonal1
  • Neoplasm, Plasma Cell1
  • Blood Protein Disorders1

Other1 trial

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.